Helmut Oettle
Friedrichshafen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Reply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial," and "Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer".
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 02, 2026
Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Journal: Journal of cancer research and clinical oncology
Published: April 02, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: March 17, 2024
KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
Journal: The journal of pathology. Clinical research
Published: December 18, 2023
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 18, 2022
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation.
Journal: Journal of clinical medicine
Published: June 12, 2022
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Journal: Nature communications
Published: March 07, 2021
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study.
Journal: Frontiers in oncology
Published: February 21, 2021
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 29, 2020
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: June 18, 2020
Last Updated: 09/26/2026